This week, following up on our recent post about Merck, we had Eyes On their recent bid for Cidara Therapeutics. This time, the acquisition is made to diversify their portfolio further, adding an antiviral asset for Influenza prophylaxis. This asset, CD 388, could provide a new class of prophylaxis, outside of the current vaccines area.

At PharmaTell we keep Eyes on Strategic moves within the market. This week we're diving into Merck & Co's plans for the future. With the upcoming patent expiry for Keytruda, they are planning to bolster their pipeline with new products and indications via internal development and M&A.

We're keeping Eyes On Diabesity. With new approvals, data on the horizon, and M&A to bolster pipelines, it seems like there's something new everyday. Here we cover new MACE indications and the Metsera bidding war. What were you watching?

We've had Eyes on the MASH activities, and the latest M&A between Novo Nordisk and Akero Therapeutics caught our eye. In IPF, Boehringer's newly approved Jascayde...

Lately we've had Eyes On: Clinical Data, FDA news, M&A, and more. Read more about uniQure's AMT-130 data for Huntington's Disease, Roche's acquisition of 89bio for MASH, JnJ's Iconic Advance Data for Psoriasis, Lundbeck's CRL letter for PTSD, and the latest buzz around acetaminophen.

🆕 Introducing AI-Powered Insights in PharmaTell Studio. With the launch of our brand-new “Eyes on Pharma: AI Summary” feature, we’re adding artificial intelligence (AI) to the core of the PharmaTell experience helping our users find relevant insights faster than ever before.